1

Exhibit 10.2

AMENDMENT NO. 1 TO

AIRCRAFTLEASEAGREEMENT

This Amendment No. 1 to the Aircraft Lease Agreement (the “Amendment”) is made

and entered into this April 6, 2026 between Falstaff Partners LLC (“Lessor”) and

Carlyle Investment Management L.L.C. (“Lessee”) and relates to the Aircraft Lease

Agreement(the“LeaseAgreement”)enteredintobyandbetweenLessorandLessee

on April 21, 2025.

WHEREAS, Lessee and Lessor haveentered into the LeaseAgreement to provide for

theleaseofone(1)GulfstreamAerospaceCorp.modelGVI(G650ER)aircraftbearing

U.S.registrationnumberN524EA,andmanufacturer'sserialnumber6444(asfurther

definedintheLeaseAgreement,the“Aircraft”)byLessortoLesseeonthetermsand

conditions provided for therein; and

WHEREAS,LesseeandLessoragreetomakecertainamendmentstotheLease

Agreement;

NOW, THEREFORE, in consideration of and subject to the mutual covenants, terms

andconditionscontainedinthisAmendmentandforgoodandvaluableconsideration,

which is hereby acknowledged, Lessee and Lessor agree to the following:

…

BCBBANCORP, INC. AND BCB COMMUNITY BANK
EMPLOYMENT AGREEMENT



THIS EMPLOYMENT AGREEMENT (this “Agreement”) is hereby entered into effective as of June 1, 2026(the “Effective Date”), by and among BCBBancorp, Inc. (the “Company”), a New Jerseycorporation with its principal executive offices at 595Avenue C, Bayonne, New Jersey 07002(the “Bayonne Office”), BCB Community Bank,a wholly owned subsidiary of the Company (the “Bank”), and Thomas M. O’Brien (“Executive”). The Company and the Bank are sometimes referred to in this Agreement individually or together as the “Employer”.



WHEREAS, Executive and the Board of Directors of the Employer desire to enter into an employment agreement setting forth the terms and conditions of the employment of Executive and the related rights and obligations of each of the parties.



NOW, THEREFORE, in consideration of the promises and mutual covenants herein contained, it is hereby agreed as follows:

…

US-DOCS\174107917.9 LIMITED WAIVER AGREEMENT This LIMITED WAIVER AGREEMENT (this “Agreement”), dated as of July 31, 2026, is by and among HUDSON PACIFIC PROPERTIES, L.P., a Maryland limited partnership (the “Borrower”), the Guarantors party hereto (solely for purposes of Section 5.5 hereof), the Lenders party hereto, and WELLS FARGO BANK, NATIONAL ASSOCIATION, as Administrative Agent (the “Administrative Agent”). WITNESSETH: WHEREAS, the Borrower, each of the lenders from time to time party thereto (each a “Lender” and, collectively, the “Lenders”), the Administrative Agent, and certain other financial institutions have entered into that certain Fourth Amended and Restated Credit Agreement, dated as of December 21, 2021 (as amended by that certain First Modification Agreement, dated as of September 15, 2022, that certain Second Modification Agreement, dated as of December 22, 2023, that certain Third Modification Agreement, dated as of May 3, 2024, that certain Fourth Modification Agreement, dated as of January 29, 2025, that certain Fifth Modification Agreement, dated as of Septemb

…

FOURTH AMENDMENT TO CREDIT AGREEMENT

This Fourth Amendment to Credit Agreement, dated as of August 7, 2026 (this “Agreement”), by and among AIRSCULPT TECHNOLOGIES, INC., a Delaware corporation (“Holdings”), EBS INTERMEDIATE PARENT LLC, a Delaware limited liability company (“Intermediate Holdings”), EBS ENTERPRISES LLC, a Delaware limited liability company (the “Borrower”), the Lenders party hereto and FIRST-CITIZENS BANK & TRUST COMPANY (“FCB”), as Administrative Agent, Issuing Lender and Swingline Lender.

W I T N E S S E T H:

…

SECOND ADDENDUM TO LETTER OF INTENT AND ADVISORY SERVICES AGREEMENT

This Second Addendum (the “Addendum”) is entered into as of June 11, 2026, by and between **NeOnc Technologies Holdings, Inc. **(“NeOnc” or the “Company”) and **AFH Holding & Advisory, LLC **(“AFH”).

RECITALS

WHEREAS, the parties entered into a Letter of Intent dated December 19, 2022 (the “Original LOI”), pursuant to which AFH agreed to provide strategic advisory, capital markets, financing, merger and acquisition, corporate governance, and public company advisory services to the Company;

WHEREAS, the Original LOI contemplated that AFH would serve as the Company’s exclusive financial advisor and receive compensation equal to two percent (2.0%) of the Company’s post-money valuation following the completion of the Company’s public offering;

WHEREAS, the parties desire to clarify and memorialize the methodology for determining such compensation using the Company’s fully diluted market capitalization.

AGREEMENT

…

** **

ENVOY MEDICAL, INC.

** **

AMENDED AND RESTATED
2023 EQUITY INCENTIVE PLAN

** **

RSU AWARD GRANT NOTICE

Envoy Medical, Inc. (the “Company”) has awarded to you (the “Participant”) the number of restricted stock units specified on the terms set forth below in consideration of your services (the “RSU Award”). Your RSU Award is subject to all of the terms and conditions set forth herein and in the Company’s Amended and Restated 2023 Equity Incentive Plan (as it may be amended or restated from time to time, the “Plan”) and the Award Agreement (the “Agreement”), which are incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Agreement shall have the meanings set forth in the Plan or, if not set forth in the Plan, the Agreement.

…

AMENDMENT NO. 5 TO THE

SONIDA SENIOR LIVING, INC.

2019 OMNIBUS STOCK AND INCENTIVE PLAN

THIS AMENDMENT NO. 5 TO THE SONIDA SENIOR LIVING, INC. 2019 OMNIBUS STOCK AND INCENTIVE PLAN (this “Amendment”), is made effective upon the approval of the stockholders of the Company of this Amendment (the “Effective Date”). All capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Plan (as defined below).

RECITALS

WHEREAS, Sonida Senior Living, Inc. (the “Company”) maintains the Company 2019 Omnibus Stock and Incentive Plan, as amended (the “Plan”);

WHEREAS, pursuant to the Plan, the Board of Directors of the Company (the “Board”) has the authority to amend the Plan from time to time; and

WHEREAS, the Board approved this Amendment pursuant to a resolution of the Board.

NOW, THEREFORE, BE IT RESOLVED, that the Plan is hereby amended as follows, effective as of the Effective Date:

AMENDMENT

1.The first sentence of Section 3.1 of the Plan is hereby deleted and replaced in its entirety with the following:

…

Separation Agreement and Release

This Separation Agreement and Release (“Agreement”) is made by and between James Malone (“Executive”) and Latch, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”).  Capitalized terms used but not defined in this Agreement shall have the meanings set forth in the Employment Agreement (as defined below).

WHEREAS, the Parties have previously entered into that certain Employment Agreement, dated as of April 10, 2026 (the “Employment Agreement”) and that certain Covenant Agreement (as defined in the Employment Agreement); and

…

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.

[***] INDICATES THAT INFORMATION HAS BEEN REDACTED.

AMENDMENT NO. 2

TO THE FRAMEWORK AGREEMENT

This Amendment No. 2 to the Framework Agreement (this “Amendment”) is made effective on the last date of mutual signature below (the “Amendment Effective Date”), by and between Heron Therapeutics, Inc., a Delaware corporation (“Heron”) and Patheon Austria GmbH & Co KG (“Patheon”). Patheon and Heron are each sometimes referred to herein as a “Party” and collectively as the “Parties”.

WHEREAS, the Parties entered into that certain Framework Agreement, with an effective date of August 6, 2025, as amended by Amendment No. 1 effective November 13, 2025 (the “Agreement”); and

WHEREAS, the Parties now desire to amend the Agreement accordingly, but only in strict accordance with, and as more particularly described in this Amendment.

…

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.

[***] INDICATES THAT INFORMATION HAS BEEN REDACTED.

AMENDMENT NO. 1 TO

FRAMEWORK AGREEMENT

This Amendment No. 1 to the Framework Agreement (this “Amendment”) is made effective on the last date of mutual signature below (the “Amendment Effective Date”), by and between Heron Therapeutics, Inc., a Delaware corporation (“Heron”) and Patheon Austria GmbH & Co KG (“Patheon”). Patheon and Heron are each sometimes referred to herein as a “Party” and collectively as the “Parties”.

WHEREAS, the Parties entered into that certain Framework Agreement, with an effective date of August 6, 2025 (the “Agreement”); and

WHEREAS, the Parties now desire to amend the Agreement accordingly, but only in strict accordance with, and as more particularly described in this Amendment.

…

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.

[***]INDICATES THAT INFORMATION HAS BEEN REDACTED.

Execution Version

WAIVER, CONSENT, AND FOURTH AMENDMENT TO WORKING CAPITAL FACILITY AGREEMENT

THIS WAIVER, CONSENT AND FOURTH AMENDMENT TO WORKING CAPITAL FACILITY AGREEMENT (this “Amendment”), dated as of August 7, 2026 (the “FourthAmendment Execution Date”), is made among HERON THERAPEUTICS, INC., a Delaware corporation (the “Borrower”), HERCULES CAPITAL, INC. (“Hercules”), in its capacity as administrative agent and collateral agent for itself and Lenders (in such capacity, together with its successors and assigns, the “Agent”) and the financial institutions or entities from time to time party hereto, including Hercules in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”).

A.

…

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

Revenue Participation Right

Purchase and Sale Agreement

By and Between

Apogee Therapeutics, Inc.

and

Annapurna Aggregator L.P.

Dated as of May 26, 2026

---

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

TABLE OF CONTENTS

…